Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Research & Development (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Research & Development readings, the most recent being $4.5 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 12.82% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.3 million, a 1.49% decrease, with the full-year FY2025 number at $20.3 million, down 1.49% from a year prior.
  • Research & Development hit $4.5 million in Q4 2025 for Treace Medical Concepts, down from $4.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.6 million in Q1 2025 to a low of $1.9 million in Q1 2021.
  • Median Research & Development over the past 5 years was $4.0 million (2022), compared with a mean of $4.0 million.
  • Biggest five-year swings in Research & Development: soared 146.64% in 2021 and later decreased 12.82% in 2025.
  • Treace Medical Concepts' Research & Development stood at $3.4 million in 2021, then rose by 11.02% to $3.7 million in 2022, then increased by 10.75% to $4.2 million in 2023, then grew by 25.48% to $5.2 million in 2024, then dropped by 12.82% to $4.5 million in 2025.
  • The last three reported values for Research & Development were $4.5 million (Q4 2025), $4.7 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.